Posted in AstraZeneca, Boehringer Ingelheim, J&J, Johnson and Johnson, Pharma, Pharma News, Pharmaceutical, Top News, Training Needs, tagged AstraZeneca, Boehringer Ingelheim, compliance training, drug reps, flibanserin, hailstorm, HSDD, J&J, red meat, Sales on May 19, 2010|
Sometimes I can’t help but voice a bit of skepticism, especially when it comes to sexual disorder treatments. So, count me as less than convinced about this experimental treatment from Boehringer-Ingelheim – Data from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebo…more (the single-question Patient Benefit Evaluation appears to me to be really…ummm…meaningful).
Lung cancer preventer for former smokers? Interesting – A drug approved to treat a range of conditions may also work to prevent lung cancer in people who have given up smoking, U.S. researchers reported on Tuesday…more
AstraZeneca replaces Nexium sales force with telemarketers. And it works.
J&J‘s recall of OTC products. This is becoming a huge black eye, for a company that managed to keep quite a good reputation over the years. It will be an interesting case study of reputation management and quality improvement, esp. for a company that has been a leader in social media usage in this sector.
Compliance and Diversity. The Impactiviti partner network has the providers you need for corporate training – including diversity, compliance, ethics, and much more! Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
Red Meat – maybe this picture isn’t so simple after all. Intuitively, this result is actually not too surprising. AND – Are you in a Museum?
JUST FOR FUN
I only rarely get to see hailstorms. That’s what makes this video particularly awesome. Must be seen to be believed!
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
Read Full Post »
Posted in AstraZeneca, Cephalon, Pfizer, Pharma, Pharma News, Pharmaceutical, Top News, Training, Web, Wyeth, tagged AstraZeneca, Cephalon, enzon, ipad, Pfizer, sigma-tau on January 28, 2010|
Pfizer trimming pipeline projects after Wyeth acquisition – Pfizer Inc., the world’s biggest drugmaker, said Wednesday it is quitting plans to sell popular pain drug Lyrica as an add-on treatment for anxiety as it shaves about 100 projects from its combined portfolio after swallowing rival Wyeth…more
AstraZeneca: 8,000 more cuts coming. Ouch – The reduction will take place by 2014 and comes on top of approximately 12,600 jobs the drugmaker has already cut. The jobs will be eliminated from sales and marketing, R&D, and supply chain operations, along with basic infrastructure…more
Cephalon shuffling the executive leadership suite.
Enzon selling specialty pharma biz to Sigma-tau.
Apple’s new iPad – gamechanger for eHealth? I say Yes – here’s why.
On-line/e-mail learning reinforcement – The event is over. Now, how do you reinforce the learning and track uptake? Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
Governments, pharma, and canceling orders. I agree with Vasella’s perspective about binding contracts.
JUST FOR FUN
Read Full Post »
Posted in AstraZeneca, Genentech, Glaxosmithkline, GSK, Pharma, Pharma News, Pharmaceutical, Roche, Top News, tagged AstraZeneca, Genentech, Hoffmann–La Roche, Roche Holding AG on January 30, 2009|
The cuts continue – this time it’s AstraZeneca. U.K.-based drugmaker AstraZeneca PLC (AZN) Thursday forecast flat 2009 sales and unveiled plans to cut a further 7,400 jobs worldwide by 2013, while posting a 1.4% decline in fourth-quarter net profit.
Roche goes hostile in bid for Genentech. Roche cut the price of its bid for outstanding shares in Genentech, going hostile and dashing investor hopes of a sweetened offer for the 44 percent of the U.S. biotech group its does not already own. Roche Holding AG’s new and lower offer, pitched directly to shareholders, was a surprise and reflected tougher financing conditions and a drop in Genentech Inc shares, analysts said on Friday.
Glaxo pays out big over marketing probe. GlaxoSmithKline is the latest drugmaker to pay the price for a government investigation of off-label marketing. The company said it’s taking a $400 million hit over a Justice Department investigation of the way Glaxo marketed top drugs.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Join a Linkedin Pharma Professionals Networking Group.
Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs. This “matchmaking” service is provided free to clients.
Read Full Post »